Anti-CD19/CD22 CAR-T cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-CD19/CD22 CAR-T cell therapy, covering 2025-09-09 to 2025-09-09. Get the full timeline:
Most recent: Clinical Trial Update: This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma. [Phase 1, Phase 2]